Results 11 to 20 of about 14,439 (224)
Biosimilars will soon become broadly available in the oncology field, raising important questions from both patients and healthcare providers. These questions need to be clarified upfront, in order to increase confidence in using these therapies. In this podcast, Teresa Amaral (Young Oncologist Committee member) talks to Josep Tabernero (ESMO President
Tabernero, Josep, Josep Tabernero
openaire +4 more sources
Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian ...
Dmitry Karateev
exaly +3 more sources
The Coming of Age of Biosimilars: A Personal Perspective
Biosimilars have come of age over the past 17 years, with 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While the acceptance of biosimilars in the US is catching up with that in the EU, the cost benefits remain ...
Sarfaraz Khan Niazi
exaly +3 more sources
Biosimilars of anti-VEGF agents in retinal diseases: a narrative review of regulatory, clinical, and pharmacoeconomic aspects [PDF]
Background Anti-vascular endothelial growth factor (anti-VEGF) agents are the cornerstone therapy for retinal vascular diseases including neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Yuan Zong, Qiwei Fan, Lijun Huang
doaj +2 more sources
Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge [PDF]
Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo +2 more
doaj +1 more source
Monoclonal antibody biosimilars for cancer treatment [PDF]
Summary: Monoclonal antibodies are important cancer medicines. The European Medicines Agency (EMA) approved 48 and the Food and Drug Administration (FDA) 56 anticancer monoclonal antibody-based therapies.
Linda N. Broer +6 more
doaj +2 more sources
Biosimilars for Haematologic Malignancies: The Path to Sustainable Care
The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes +2 more
doaj +1 more source
Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+9 more sources
Biosimilars - drugs of the future [PDF]
The article describes the basic terms and definitions relating to biosimilars, generics and original drugs. Also described a brief history of the origin and development of the biotechnology industry and drugs produced using biological objects.
E. A. Eltcova +3 more
doaj +1 more source
An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Sara Nunes +2 more
exaly +3 more sources

